Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta, MD, an associate professor at the University of Alabama at Birmingham Comprehensive Cancer Center, discusses the toxicity profile of the first-in-class PI3Kδ inhibitor parsaclisib, according to findings from this agent in the phase 2 CITADEL-205 clinical trial (NCT03235544) of relapsed/refractory mantle cell lymphoma (MCL).
Parsaclisib is a highly specific PI3Kδ inhibitor compared with the other PI3Kδ inhibitors, and it was designed to reduce transaminitis as a side effect, says Mehta. This study aimed to explore the efficacy and safety of this therapy.
Overall, the occurrence of transaminitis was very low, especially in terms of grade 3/4 toxicity, which occurred in about 3% to 4%. Diarrhea was observed, which is a known class side effect, according to Mehta. Grade 3 or higher diarrhea occurred in about 13% of patients in the study, and for about half of the patients, this was reason for discontinuation.
Mehta says physicians have learned to be proactive about this side effect. If a patient has diarrhea, physicians should act quickly to manage it.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More